imidaprilat   Click here for help

GtoPdb Ligand ID: 6378

Approved drug
imidaprilat is an approved drug (FDA)
Compound class: Synthetic organic
Comment: This drug is produced as the active metabolite of the prodrug imidapril
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 127.25
Molecular weight 377.16
XLogP 0.3
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC(C(=O)N1C(=O)N(CC1C(=O)O)C)NC(C(=O)O)CCc1ccccc1
Isomeric SMILES C[C@@H](C(=O)N1C(=O)N(C[C@H]1C(=O)O)C)N[C@H](C(=O)O)CCc1ccccc1
InChI InChI=1S/C18H23N3O6/c1-11(15(22)21-14(17(25)26)10-20(2)18(21)27)19-13(16(23)24)9-8-12-6-4-3-5-7-12/h3-7,11,13-14,19H,8-10H2,1-2H3,(H,23,24)(H,25,26)/t11-,13-,14-/m0/s1
No information available.
Summary of Clinical Use Click here for help
The prodrug is administered to treat hypertension and congestive heart failure.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Imidaprilat competes with angiotensisn I for binding to ACE thereby inhibiting its enzymatic conversion to angiotensin II. Reduced levels of angiotensin II leads to reduced blood pressure by modifying the renin-angiotensin system (RAS).